Crizotinib (Xalkori) and
trametinib (Mekinist) have both
been listed on the Pharmaceutical
Benefits Scheme via a Managed
Entry Scheme (MES).
An MES provides “a means by
which to address the uncertainty
over the clinical benefit of a
medicine while providing early
access to those patients for whom
there is a high clinical need,” the
Health Department said.
Prescribers and patients are
advised that if the drugs do not
prove as beneficial in practice as
in clinical data presented to the
PBAC, they may have their listings
modified, or they may be removed
from the PBS.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Aug 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Aug 15
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.